Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Back

ESC Premium Access

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Session: Pharmacology and Pharmacotherapy ePosters

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor Y. Huo (Beijing, CN)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Professor Yong Huo

Peking University First Hospital, Beijing (China)

0 follower

56 more presentations in this session

Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects

Speaker: Doctor C. Becker (Wuppertal, DE)

Access

Abstract

Slides

Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics

Speaker: Doctor S. Frechen (Leverkusen, DE)

Access

Abstract

Slides

Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study

Speaker: Doctor C. Ballantyne (Houston, US)

Access

Abstract

Slides

The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population

Speaker: Doctor D. Radenkovic (Greater London, GB)

Access

Abstract

Slides

Adherence to high-intensity statin therapy after acute coronary syndrome and its impact on patient outcome

Speaker: Doctor P. Sulzgruber (Vienna, AT)

Access

Abstract

Slides

Access the full session

Pharmacology and Pharmacotherapy ePosters

Speakers: Professor Y. Huo, Doctor C. Becker, Doctor S. Frechen, Doctor C. Ballantyne, Doctor D. Radenkovic...

Access

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources